2-hydroxyglutaric acid

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 1586 references associated with 2-hydroxyglutaric acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2-hydroxyglutaric acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-hydroxyglutaric acid

MeSH term MeSH ID Detail
Phenylketonurias D010661 7 associated lipids
Canavan Disease D017825 2 associated lipids
Metabolic Diseases D008659 12 associated lipids
Tyrosinemias D020176 2 associated lipids
Hyperoxaluria D006959 3 associated lipids
Total 5

PubChem Associated disorders and diseases

PubChem Biomolecular Interactions and Pathways

NCBI Entrez Crosslinks

All references with 2-hydroxyglutaric acid

Download all related citations
Per page 10 20 50 100 | Total 448
Authors Title Published Journal PubMed Link
Cairns RA and Mak TW Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. 2013 Cancer Discov pmid:23796461
DiNardo CD et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. 2013 Blood pmid:23641016
Losman JA and Kaelin WG What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. 2013 Genes Dev. pmid:23630074
Choi C et al. A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. 2013 NMR Biomed pmid:23592268
Nota B et al. Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. 2013 Am. J. Hum. Genet. pmid:23561848
Wang F et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. 2013 Science pmid:23558173
Rohle D et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. 2013 Science pmid:23558169
Juratli TA et al. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. 2013 Neuro-oncology pmid:23410661
Losman JA et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. 2013 Science pmid:23393090
Ward PS et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. 2013 J. Biol. Chem. pmid:23264629
Jin G et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. 2013 Cancer Res. pmid:23204232
Natsumeda M et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. 2014 Acta Neuropathol Commun pmid:25376594
Chittaranjan S et al. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. 2014 Oncotarget pmid:25277207
Liu Z et al. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. 2014 J. Med. Chem. pmid:25271760
Shim EH et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. 2014 Cancer Discov pmid:25182153
Saha SK et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. 2014 Nature pmid:25043045
Pope WB Intraoperative mass spectrometry of tumor metabolites. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:25028494
Reitman ZJ et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. 2014 J. Biol. Chem. pmid:24986863
Santagata S et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:24982150
Kato Kaneko M et al. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. 2014 Cancer Sci. pmid:24898068
Fathi AT et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. 2014 Oncologist pmid:24760710
Elhammali A et al. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. 2014 Cancer Discov pmid:24740997
Tarhonskaya H et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. 2014 Nat Commun pmid:24594748
Akbay EA et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. 2014 Genes Dev. pmid:24589777
Pusch S et al. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. 2014 Acta Neuropathol Commun pmid:24529257
Menendez JA et al. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. 2014 Cell Cycle pmid:24526120
Borger DR et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. 2014 Clin. Cancer Res. pmid:24478380
Işıkay S et al. A child with L-2 hydroxyglutaric aciduria presenting with dilated cardiomyopathy: coincidence or a new syndrome? 2014 Anadolu Kardiyol Derg pmid:24382499
Terunuma A et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. 2014 J. Clin. Invest. pmid:24316975
Gilbert MR et al. Autophagy and oxidative stress in gliomas with IDH1 mutations. 2014 Acta Neuropathol. pmid:24150401
Wang P et al. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. 2015 Cell Rep pmid:26686626
Tateishi K et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. 2015 Cancer Cell pmid:26678339
Oldham WM et al. Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. 2015 Cell Metab. pmid:26212716
Tai H and Zhang Z A novel compound heterozygous mutation in a Chinese boy with L-2-hydroxyglutaric aciduria: a case study. 2015 BMC Neurol pmid:26208971
Fu X et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. 2015 Cell Metab. pmid:26190651
Hwang VJ et al. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. 2015 Am. J. Physiol. Renal Physiol. pmid:26155843
Macaulay RJ Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. 2015 Cancer Control pmid:26068765
Suijker J et al. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. 2015 Oncotarget pmid:26046462
Izquierdo-Garcia JL et al. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. 2015 Cancer Res. pmid:26045167
Pichumani K et al. Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas. 2015 Anal. Biochem. pmid:25908561
Lombardi G et al. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. 2015 Oncologist pmid:25862748
Pellegatta S et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. 2015 Acta Neuropathol Commun pmid:25849072
Ma S et al. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. 2015 Oncotarget pmid:25825982
Oizel K et al. D-2-Hydroxyglutarate does not mimic all the IDH mutation effects, in particular the reduced etoposide-triggered apoptosis mediated by an alteration in mitochondrial NADH. 2015 Cell Death Dis pmid:25811801
Keum YS and Choi BY Isocitrate dehydrogenase mutations: new opportunities for translational research. 2015 BMB Rep pmid:25787993
Shi X et al. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish. 2015 Blood pmid:25778530
Rzem R et al. A mouse model of L-2-hydroxyglutaric aciduria, a disorder of metabolite repair. 2015 PLoS ONE pmid:25763823
Hirata M et al. Mutant IDH is sufficient to initiate enchondromatosis in mice. 2015 Proc. Natl. Acad. Sci. U.S.A. pmid:25730874
Charitou P et al. FOXOs support the metabolic requirements of normal and tumor cells by promoting IDH1 expression. 2015 EMBO Rep. pmid:25648147
Chan SM et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. 2015 Nat. Med. pmid:25599133